Intuitive Surgical Nails Q1 But Dips Anyway

Intuitive Surgical found itself getting examined for signs of weakness after the bell Tuesday, even after posting a quarter most companies would treat like a clean bill of corporate health. The company reported first-quarter revenue of $2.77 billion, up 23% from a year earlier, while adjusted earnings rose to $2.50 a share from $1.82. Worldwide procedures grew about 17%, and Intuitive raised its 2026 procedure-growth outlook to 13.5% to 15.5%. By any ordinary standard, the quarter should have been strong enough to buy the company at least one quiet night.

Alas, Intuitive has reached the stage where strong results do not automatically buy peace and quiet. Investors were left parsing what came after the beat — a full-year growth outlook that still points to some cooling from 2025’s pace, rising competitive pressure in robotic surgery, and the general burden of being a premium stock that gets graded like it is taking an exam every quarter. For all the nitpicking that followed, the quarter still showed a business running with surgical precision.

Intuitive placed 431 da Vinci systems in the quarter, including 232 of its newest da Vinci 5 models, while system revenue climbed to $651 million and instruments and accessories revenue rose to $1.69 billion. The company’s ecosystem keeps spreading through operating rooms one robot at a time. The installed base reached 11,395 da Vinci systems and 1,041 Ion systems. That is not the profile of a company drifting off course, just one being held to an absurdly high standard.

The catch is that excellence has become the minimum admission price here. Intuitive projected 2026 non-GAAP gross margin of 67.5% to 68.5%, including an estimated tariff impact equal to about 1.0% of revenue, and that was enough to keep some investors from celebrating too freely, because no high-tech growth case is complete until tariffs wander in and put a thumb on the margin. Even so, Intuitive still looks like one of medtech’s cleanest operators, while Wall Street treats even a very good report as an invitation to ask what could possibly go wrong next.

Disclaimer: This content is for informational and entertainment purposes only and does not constitute financial or investment advice. The information provided may be outdated or contain inaccuracies. Always conduct your own due diligence and consult a licensed financial advisor before making investment decisions. Investing involves risk, including the potential loss of principal. Unless explicitly stated otherwise, neither Equiscreen, LLC nor its beneficial owners hold any financial interest in the companies mentioned in our articles, and we do not receive compensation for including them. Equiscreen, LLC and its beneficial owners may buy or sell securities of any company referenced in our content at any time and without prior notice, and nothing published by Equiscreen, LLC should be interpreted as a recommendation to buy, sell, or hold any security. Any paid content or income-related materials will be clearly identified as “Sponsored” or “Advertorial,” and corresponding income disclosures can be found at the bottom of the page. For additional information, please contact [email protected].

Top Gainers

Top Losers

U.S. Commodities

2234 N Federal Hwy # 1022
Boca Raton, FL 33431

(561) 264-5726